The 2023 J&J Innovative Medicine U.S. Pricing Transparency Report

At Johnson & Johnson, we are leading where medicine is going

J&J is advancing the next era of medical innovation through our continuous R&D investments, totaling $77.7 billion since 2016.¹ However, patients’ cost exposure and access challenges are increasing because of distorted insurance benefit design and regulatory hurdles.

The text "Since 2016, J&J IM has invested more than $77B in R&D" is separated into two sections with enlarged red accented backgrounds.

J&J’s R&D investments: Making the hope of innovation a reality for patients in the next decade…and beyond

How J&J is advancing the next era of healthcare advancements for patients:

$12B

In 2023, J&J Innovative Medicine invested $12 billion to develop pharmaceutical treatments and cures¹

>124%

In 2023, J&J Innovative Medicine spent over 124% more on pharmaceutical R&D than sales and marketing¹

70+

J&J aims to launch or file more than 70 novel therapies and expanded treatment options for patients by 2030²

But patients still face significant barriers to access

When health insurance works as intended, insured patients can affordably access their treatments when they need to. But for millions of Americans, health insurance does not fulfill this basic purpose.³

Pharmacy benefit managers (PBMs) create barriers to access by implementing restrictive programs like prior authorization, step therapy and formulary exclusions, which hinder provider and patient healthcare decision-making.⁴ Additionally, distortions in health insurance benefit design and underinsurance leave many patients financially exposed and unable to afford necessary treatments, disproportionately impacting vulnerable populations.³

A text call-out displays "It’s a constant struggle all day long" in enlarged red text followed by "Pharmacist Mark Stahl on a patient who was forced to pay more than $300 out of pocket for an inhaler — about $60 more than he would have had to pay for the generic version that his PBM no longer covers."

Our responsibility to patients

At J&J, we understand our dual responsibility to patients: (1) to develop the next generation of medicines across a vast continuum of diseases for the patients of tomorrow and (2) to help support affordable access to our medicines.

To meet these responsibilities we have to patients, the healthcare system and society, we consider three factors when pricing our medicines:

The value they bring to patients, the healthcare system and society

The need to further support patient access

The need to continue innovating and developing new and novel medicines for the patients of today and tomorrow

Drug list prices are simply a starting point

Manufacturers like Johnson & Johnson support patients' access to their medicines through vigorous private market negotiations with health insurance companies, PBMs and other intermediaries that dispense medications (e.g. hospitals and clinics).

Our net prices have declined by nearly 20% over the past seven years.⁶ Despite lower net prices paid by insurers for our medicines, millions of patients are still facing higher costs and barriers to access, and some are even having patient assistance taken from them.

A white half circle surrounded in bright red descends into a full circle with the text "-18.6% drop in our net prices since 2016" inside.

One way J&J supports patient access: Rebates, discounts and fees

In 2023, we provided $42.8 billion in rebates, discounts and fees to insurers, pharmacy benefit managers (PBMs), hospitals, government programs and other healthcare entities.⁶

A multicolor pie graph is split into the following nine sections:
$13.4B (31%) to private insurers and PBMs
$6.0B (14%) to 340B
$5.9B (14%) to Medicare
$4.8B (11%) to community clinics
$4.3B (10%) to Medicaid programs
$4.0B (9%) to other healthcare entities
$2.0B (5%) to distributors
$1.7B (4%) to the VA and DOD
$0.7B (2%) to non-340B hospitals.

A multicolor graph is split into the following nine sections:
$13.4B (31%) to private insurers and PBMs
$6.0B (14%) to 340B or PHS designated hospitals and sites of care
$5.9B (14%) to Medicare
$4.8B (11%) to community clinics
$4.3B (10%) to Medicaid programs
$4.0B (9%) to other healthcare entities*
$2.0B (5%) to distributors
$1.7B (4%) to the VA, DOD and other government service organizations
$0.7B (2%) to non-340B hospitals.

Our rebates, discounts and fees have risen significantly from 2016 to 2023⁶

This infographic titled "Rebate growth since 2016" uses a bar chart to contrast statistics from 2016 with those from 2023. They are labeled as follows. Rebates to...
a) Medicaid grew from 1.4 billion to 4.3 billion
b) Community clinics grew from 1.5 billion to 4.8 billion
c) Medicare grew from 1.3 billion to 5.90 billion
d) 340B programs grew from 2 billion to 6 billion
e) Private insurers and PBMs grew from 1.7 billion to 13.4 billion.

This infographic titled "Rebate growth since 2016" uses a circle chart to contrast statistics from 2016 with those from 2023. They are labeled as follows:
Medicaid grew 3 times, from 1.4 billion to 4.3 billion
Community clinics grew 3.2 times, from 1.5 billion to 4.8 billion
Medicare grew 4.5 times, from 1.3 billion to 5.90 billion
340B programs grew 3 times, from 2 billion to 6 billion
Commercial payers and pharmacy benefit managers increased 8 times, growing from 1.7 billion to 13.4 billion.

Patients are not directly benefiting from lower net prices 

We negotiate lower net prices to expand access and to make drugs more affordable for patients, not to benefit middlemen and other intermediaries.

The gap between U.S. list prices, which is what we charge insurance companies, and net prices for brand name medicines, which is after rebates and discounts provided to private insurers and other intermediaries, grew by 45% from 2017 to 2022.⁷

A line chart compares list prices and net prices from the years 2016 to 2023, showing a steep decline in net price change and only a slight decline in list price.

Supporting affordable access:
Three ways to lower patient costs

Remove barriers to patient access to medicines by changing distorted insurance benefit design

Prevent middlemen from diverting patient assistance away from patients

Base patient cost-sharing on lower net prices accounting for discounts given to payers

The real impact of rising out-of-pocket costs

A wide bright red image is sectioned into three sections each with a caption and infographic. The left section shows a horizontal bar graph that reads "2016 to 2022, out-of-pocket costs rose 26%". The middle section says "According to an independent study, total OOP costs are expected to grow at an annual rate of 9.9% which would result in almost $800 billion in consumer OOP healthcare spending in 2026.9" with an iPhone timer displaying 5 seconds. Above the timer is the text "In other words, every five seconds, out-of-pocket costs will increase by $127,000." The section on the right says "When patient costs exceed $250, more than half of patients abandon their newly prescribed treatment" above five people waiting in line, three of which are only outlines.

The summary

42% of all discounts, rebates and fees goes to government programs⁶

Nearly 1/3 of discounts, rebates and fees goes to health insurers and PBMs⁶

Patients are not directly benefiting from these growing savings

Policy challenges to the innovation ecosystem

Incentivizing risk-taking is a critical part of advancing medicine for patients, but many policies (either enacted or under consideration) could severely undermine the innovation ecosystem that has delivered healthcare advancements for patients.

Stop government price-setting

At the federal level, concerns are mounting that government-mandated prices could upend the process of drug discovery and development or tie U.S. drug prices to those in foreign countries. At the state level, prescription drug affordability boards (PDABs) and upper payment limits (UPLs) on branded medications have gained momentum — but these policies have significant drawbacks. Read more here.

Preserve the value of innovation

Current law has many provisions to protect abuse of patent practices. Limiting the ability to protect inventions or enforce patent rights associated with pharmaceutical innovation is an unnecessary measure and would upend the R&D innovation ecosystem that advances treatments for patients today, as well as pharmaceutical innovations for years to come.

Intellectual property rights: Limiting the ability to protect inventions or enforce patent rights associated with pharmaceutical innovation would upend the R&D innovation ecosystem that advances treatments for patients today, as well as pharmaceutical innovations for years to come.
“Marching in”: The 1980 Bayh-Dole Act was passed to promote the use of inventions and spur collaboration between government funded entities and innovative companies with the expertise and capabilities necessary to develop and commercialize innovative products,¹¹ It was never intended to be used as a price setting mechanism, nor as a tool to seize intellectual property rights based on a government dictated “reasonable” price. If the government “marches in” and licenses patent rights to widely available treatments, public-private sector collaboration and the innovation ecosystem will suffer.¹²

Keep decisions up to patients & providers

Misaligned incentives in the market and in programs like 340B have strengthened middlemen like PBMs, whose growing use of restrictions and opaque operating models are creating significant hurdles for providers and patients to make the right healthcare decisions. Policies should protect the patient-physician relationship and eliminate the undue influence of commercial payers on patient health decisions.

R&D: A process of inherent risk

The innovation ecosystem also needs policies and regulations that bolster scientific advancement. Discovering and developing life-saving medicines requires significant resources and cooperation between researchers and regulators.

On average, it takes more than 12 years and $4 billion, including cost of capital for the total lifecycle, to bring a new medicine to market.^{14, 15}

A pie chart is filled in 93% bright red. Above, the text reads "Approximately 93% of the drugs that enter clinical trials fail before they can make it to market."

The 340B Program: Diversion and duplicate discounts are hurting vulnerable patients

The 340B program was designed by Congress to be a very limited, targeted program enabling manufacturers to restore deep discounts that manufacturers historically had provided voluntarily to safety net providers. However, the program has grown out of control as for-profit pharmacy chains and larger health systems have used it to boost profits without directly benefiting patients.

Read our 340B brief to learn more about the growing problems with the 340B program — and how to fix them.

How we fix 340B

An infographic is split into two sections. The top section states that "Purchases by covered entities at discounted 340B prices have risen precipitously." above a bar graph showing a 246% increase. The bottom section displays a Venn diagram titled "How we fix 340 B". The left circle says "Eliminate duplicate discounts and diversion". The middle circle says "Provide a robust patient definition". The right circle says "Require 340B discounts to be shared directly with needy patients".

Making healthcare policy work for patients

We pursue health solutions that keep patients at the center. We also consider the experiences of our patients, who use our medicines every day, the perspectives of our scientists and researchers discovering the next medical breakthrough and our concerns about the misaligned incentives in the marketplace. Specifically, we think the following is needed:

Reform PBMs to prevent patient access hurdles, lower patient costs and promote patient-provider decision making

Reform the 340B program to support its original intent, building increased transparency and accountability

Stop patient assistance diversion programs and prevent the spread of alternative funding programs (AFPs)

Enact policies that preserve the innovation ecosystem that enables the discovery and development of cures

Looking back at the Orphan Drug Act: What better policy can deliver for patients

To encourage manufacturers to address unmet patient needs for orphan drugs, which treat rare diseases, in 1983 the federal government passed the Orphan Drug Act (ODA). Under the ODA, a company may qualify for research grants, tax credits for qualified clinical trials and potential seven-year market exclusivity after a drug’s approval.¹⁹

The result: Before the ODA was passed, the FDA had approved just 38 orphan drugs to treat rare diseases. Today, more than 650 orphan drugs have been approved by the FDA—with more in development.¹⁸

A large red circle titled "The ODA’s impact: Number of orphan drugs approved to treat rare diseases" says "650 after the ODA passed." A slim shadow shaded dark red is labeled "38 before the ODA passed".

⠀

A large textured red footer reads "We believe together, we can find solutions to address the mental health crisis, modernize regulatory pathways, provide critical access to affordable medicines and enhance diversity in clinical trials." Text in an untextured half-circle below reads "At Johnson & Johnson, we are leading where medicine is going."

Citations

Introduction

1. Figure according to Johnson & Johnson internal financial accounting. Values may have been rounded.
2. Johnson & Johnson. “J&J Innovative Medicine Business Overview.” Slide 6. December 2023. https://jnjbusinessreview.q4ir.com/files/doc_downloads/2023/12/innovative-medicine-presentation.pdf. Accessed May 2024.
3. Sara R. Collins, Lauren A. Haynes, and Relebohile Masitha. “The State of U.S. Health Insurance in 2022.” Commonwealth Fund Biennial Health Insurance Survey, The Commonwealth Fund. September 29, 2022.https://www.commonwealthfund.org/publications/issue-briefs/2022/sep/state-us-health-insurance-2022-biennial-survey.Accessed May 2024.
4. PhRMA. “Insurers and Middlemen Force Many of the Sickest Patients to Face High Out-of-Pocket Costs.” https://phrma.org/resource-center/Insurance-Coverage/Insurance-Coverage-and-PBMs.Accessed May 2024.
5. Robbins R, Abelson R. "The Opaque Industry Secretly Inflating Prices for Prescription Drugs." The New York Times. https://www.nytimes.com/2024/06/21/business/prescription-drug-costs-pbm.html.Published June 21, 2024. Accessed July 2024.

Our responsibility to patients

6. Figure according to Johnson & Johnson internal financial accounting. Values may have been rounded.
7. Adam Fein, “Gross-to-Net Bubble Update: 2022 Pricing Realities at 10 Top Drugmakers.” Drug Channels. June 2023. https://www.drugchannels.net/2023/06/gross-to-net-bubble-update-2022-pricing.html. Accessed July 2024.
8. Peterson-KFF Health System Tracker. “How has U.S. spending on healthcare changed over time?” December 15, 2023. https://www.healthsystemtracker.org/chart-collection/u-s-spending-healthcare-changed-time/#Average%20annual%20expenditures%20growth%20rate%20for%20select%20service%20types,%201970-2022. Accessed May 2024.
9. Kalorama Information. "Out-of-Pocket Healthcare Expenditures in the United States, 5th Edition." August 2, 2021. https://kaloramainformation.com/product/out-of-pocket-healthcare-expenditures-in-the-united-states-5th-edition/. Accessed May 2024.
10. IQVIA. “The Use of Medicines in the U.S. 2023, Usage and Spending Trends and Outlook to 2027.” May 2, 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-use-of-medicines-in-the-us-2023. Accessed January 2024.

Policy challenges to the innovation ecosystem

11. PhRMA. “The Role of The Bayh-Dole Act in Fostering Technology Transfer And Implications for Innovation.” February 2020. https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/A-C/Bayh-Dole-Whitepaper-FINAL---21820.pdf. Accessed January 2024.
12. PhRMA. “Proposed march-in framework would chill American innovation.” February 7, 2024. https://phrma.org/Blog/Proposed-march-in-draft-framework-would-chill-American-innovation.Accessed May 2024.
13. Dowden H, Munro J. “Trends in clinical success rates and therapeutic focus.” July 16, 2019. https://www.nature.com/articles/d41573-019-00074-z.epdf?no_publisher_access=1&r3_referer=nature. Accessed May 2024.
14. Neumann U, Proudman D, Martin S, and Grabowski HG. "Public Sector Replacement of Privately Funded Pharmaceutical R&D: Cost and Efficiency Considerations." May 5–8, 2024. https://www.ispor.org/docs/default-source/intl2024/j-j-access-policy-research---ispor-2024---government-and-industry-r-d-funding-lit137838-pdf.pdf?sfvrsn=32dc4f6b_0. Accessed May 2024.
15. McKinsey & Company. "Fast to first-in-human: Getting new medicines to patients more quickly." https://www.mckinsey.com/industries/life-sciences/our-insights/fast-to-first-in-human-getting-new-medicines-to-patients-more-quickly. Accessed July 2024.
16. IQVIA. “The 340B Drug Discount Program Grew to $124B in 2023.” May 2024. https://www.iqvia.com/-/media/iqvia/pdfs/us/white-paper/2024/iqvia-update-on-size-of-340b-program-report-2024.pdf. Accessed May 2024.
17. Adam Fein, "Exclusive: The 340B Program reached $54 billion in 2022 - Up 22% vs. 2021." Drug Channels. September 24, 2023. https://www.drugchannels.net/2023/09/exclusive-340b-program-reached-54.html. Accessed August 2024.
18. Rare Disease Company Coalition. “Building on 40 Years of the Orphan Drug Act.” December 2022. https://www.rarecoalition.com/wp-content/uploads/ODA-Overview.pdf. Accessed May 2024.
19. JNJ.com. “What is an orphan drug?” February 28, 2024. https://www.jnj.com/innovation/what-is-an-orphan-drug . Accessed May 2024.

One way J&J supports patient access: Rebates, discounts and fees

Our rebates, discounts and fees have risen significantly from 2016 to 20236

Patients are not directly benefiting from lower net prices

Our rebates, discounts and fees have risen significantly from 2016 to 2023⁶

Patients are not directly benefiting from lower net prices 